Fluzoparib increases radiation sensitivity of non-small cell lung cancer (NSCLC) cells without BRCA1/2 mutation, a novel PARP1 inhibitor undergoing clinical trials

ConclusionThe potential therapeutic value of fluzoparib for increasing the radiation sensitivity of NSCLC is well confirmed. Moreover, our findings of high mutation frequencies among HR genes suggest that PARP1 inhibition may be an effective treatment strategy for advanced non-small cell lung cancer patients.

http://link.springer.com/10.1007/s00432-019-03097-6

Source: Journal of Cancer Research and Clinical Oncology - February 25, 2020 Category: Cancer & Oncology Source Type: research